Literature DB >> 31876614

Characterization of Circulating Clostridium difficile Strains, Host Response and Intestinal Microbiome in Hospitalized Children With Diarrhea.

Emily Ann Lees1, Enitan D Carrol2, Nicholas A F Ellaby3, Paul Roberts4, Caroline E Corless4, Luca Lenzi3, Alistair Darby3, Sarah J O'Brien5, Nigel A Cunliffe2, Mark A Turner6, Fabio Miyajima1, Munir Pirmohamed1.   

Abstract

BACKGROUND: Clostridium difficile is capable of causing severe enterocolitis in adults. The significance of toxin-producing C. difficile in children with diarrhea is unclear and practice differs on whether to institute treatment. We aimed to characterize the microbiome in relation to the presence of C. difficile and co-infection with other pathogens and to describe host response to infection.
METHODS: Participants were children with acute diarrhea, 0-16 years of age, from whom stool samples had been submitted to the hospital laboratory for routine microbiology/virology. Convenience sampling was used for 50 prospective and 150 retrospective samples. No participants were treated for C. difficile. Rates of culture positivity for C. difficile, presence of toxin and PCR-ribotype were compared between age groups. Presence of other potential pathogens, comorbidities and complications were recorded. Microbiotal diversity was measured by 16S profiling.
RESULTS: Nineteen of 77 (25%) children <2 years of age and 13 of 119 (11%) children >2 years of age were C. difficile positive, of whom 10 (53%) and 9 (69%), respectively, carried toxigenic strains. Increased Shannon diversity was seen in children carrying C. difficile, with altered milieu. Presence of C. difficile was not associated with adverse clinical outcomes. In stools containing both Norovirus and C. difficile, there was increased relative abundance of verrucomicrobia.
CONCLUSIONS: Children with diarrhea regularly carried toxigenic and non-toxigenic strains of C. difficile, demonstrating enhanced microbiotal diversity, and change in milieu, without apparent morbidity. This unexpected finding is contrary to that seen in adults with C. difficile disease.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31876614     DOI: 10.1097/INF.0000000000002559

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Clostridioides difficile colonization among very young children in resource-limited settings.

Authors:  Stephanie A Brennhofer; Elizabeth T Rogawski McQuade; Jie Liu; Richard L Guerrant; James A Platts-Mills; Cirle A Warren
Journal:  Clin Microbiol Infect       Date:  2022-02-10       Impact factor: 13.310

2.  Molecular characteristics of Clostridium difficile in children with acute gastroenteritis from Zhejiang.

Authors:  Huiqun Shuai; Qiao Bian; Yun Luo; Xiaohong Zhou; Xiaojun Song; Julian Ye; Qinghong Huang; Zhaoyang Peng; Jun Wu; Jianmin Jiang; Dazhi Jin
Journal:  BMC Infect Dis       Date:  2020-05-13       Impact factor: 3.090

3.  Molecular Epidemiology and Antimicrobial Resistance of Clostridioides difficile in Hospitalized Patients From Mexico.

Authors:  Emmanuel Aguilar-Zamora; Bart C Weimer; Roberto C Torres; Alejandro Gómez-Delgado; Nayeli Ortiz-Olvera; Gerardo Aparicio-Ozores; Varenka J Barbero-Becerra; Javier Torres; Margarita Camorlinga-Ponce
Journal:  Front Microbiol       Date:  2022-03-10       Impact factor: 5.640

4.  Altered Microbiota, Impaired Quality of Life, Malabsorption, Infection, and Inflammation in CVID Patients With Diarrhoea.

Authors:  Cornelia M van Schewick; Christina Nöltner; Svenja Abel; Siobhan O Burns; Sarita Workman; Andrew Symes; David Guzman; Michele Proietti; Alla Bulashevska; Fernando Moreira; Veronika Soetedjo; David M Lowe; Bodo Grimbacher
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

Review 5.  Bacterial Gut Microbiota and Infections During Early Childhood.

Authors:  Sergio George; Ximena Aguilera; Pablo Gallardo; Mauricio Farfán; Yalda Lucero; Juan Pablo Torres; Roberto Vidal; Miguel O'Ryan
Journal:  Front Microbiol       Date:  2022-01-05       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.